Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DEXAMETHASONE

Form:

8 of 8 products shown

6 general benefit · 2 not a benefit

Other products in the same Health Canada class (H02AB, S01BA) — coverage varies; not interchangeable

  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pred Forte): general benefit, Not a benefit

7 more in the class list below

Maxidex · DIN 00042579 · 0.1% · Oph Oint-3.5g Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Maxidex · DIN 00042579 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-01-19 · brand MAXIDEX · ATC S01BA01 DEXAMETHASONE · form Ointment · route Ophthalmic · ingredients DEXAMETHASONE 0.1 %/W/W · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Maxidex: Formulary list price $9.7200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.7200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4591 · Verify on the e-Formulary ↗ (DIN 00042579)

Source record
DIN 00042579: Maxidex Raw flags: sec3=Y Item: 520800015; group id 592; item number 1550; lccId None; manufacturer id NOV Source form: Oph Oint-3.5g Pk; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $9.7200; ministry $9.7200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00042579 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4591
Shortage status: resolved shortage (ended 2025-12-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00042579
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Maxidex · DIN 00042560 · 0.1% · Oph suspension

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Maxidex · DIN 00042560 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-02-22 · brand MAXIDEX · ATC S01BA01 DEXAMETHASONE · form Suspension · route Ophthalmic · ingredients DEXAMETHASONE 0.1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Maxidex: Formulary list price $1.7900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.7900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2620 · Verify on the e-Formulary ↗ (DIN 00042560)

Source record
DIN 00042560: Maxidex Raw flags: sec3=Y Item: 520800014; group id 592; item number 1551; lccId None; manufacturer id NOV Source form: Oph Susp; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $1.7900; ministry $1.7900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00042560 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2620
Shortage status: resolved shortage (ended 2022-11-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00042560
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Dexamethasone · DIN 02261081 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Dexamethasone · DIN 02261081 Manufacturer: Apotex Inc.; listing date 2005-04-28 Health Canada: Marketed since 2004-11-17 · brand APO-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 0.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Dexamethasone: Formulary list price $0.1564/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1564 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74650 · Verify on the e-Formulary ↗ (DIN 02261081)

Source record
DIN 02261081: Apo-Dexamethasone Raw flags: sec3=Y Item: 680400022; group id 707; item number 1746; lccId None; manufacturer id APX Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.1564; ministry $0.1564 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261081 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74650
Interchangeable products
Decadron · DIN 00016462 · not recorded PMS-Dexamethasone · DIN 01964976 · $0.1564
Shortage status: resolved shortage (ended 2020-09-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02261081
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Dexamethasone · DIN 01964976 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Dexamethasone · DIN 01964976 Manufacturer: Pharmascience Inc.; listing date 1998-12-31 Health Canada: Marketed since 2023-10-11 · brand PMS-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 0.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Dexamethasone: Formulary list price $0.1564/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1564 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=23261 · Verify on the e-Formulary ↗ (DIN 01964976)

Source record
DIN 01964976: PMS-Dexamethasone Raw flags: sec3=Y Item: 680400022; group id 707; item number 1746; lccId None; manufacturer id PMS Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.1564; ministry $0.1564 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01964976 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=23261
Interchangeable products
Apo-Dexamethasone · DIN 02261081 · $0.1564 Decadron · DIN 00016462 · not recorded
Shortage status: resolved shortage (ended 2023-04-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01964976
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Dexamethasone · DIN 02250055 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Dexamethasone · DIN 02250055 Manufacturer: Apotex Inc.; listing date 2004-10-14 Health Canada: Marketed since 2004-03-08 · brand APO-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 4 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Dexamethasone: Formulary list price $0.6112/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6112 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73487 · Verify on the e-Formulary ↗ (DIN 02250055)

Source record
DIN 02250055: Apo-Dexamethasone Raw flags: sec3=Y Item: 680400031; group id 707; item number 1747; lccId None; manufacturer id APX Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.6112; ministry $0.6112 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02250055 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73487
Interchangeable products
Decadron · DIN 00354309 · not recorded PMS-Dexamethasone · DIN 01964070 · $0.6112
Shortage status: resolved shortage (ended 2025-10-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02250055
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Dexamethasone · DIN 01964070 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Dexamethasone · DIN 01964070 Manufacturer: Pharmascience Inc.; listing date 1998-12-31 Health Canada: Marketed since 2023-10-11 · brand PMS-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 4 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Dexamethasone: Formulary list price $0.6112/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6112 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=23194 · Verify on the e-Formulary ↗ (DIN 01964070)

Source record
DIN 01964070: PMS-Dexamethasone Raw flags: sec3=Y Item: 680400031; group id 707; item number 1747; lccId None; manufacturer id PMS Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.6112; ministry $0.6112 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01964070 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=23194
Interchangeable products
Apo-Dexamethasone · DIN 02250055 · $0.6112 Decadron · DIN 00354309 · not recorded
Shortage status: resolved shortage (ended 2020-09-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01964070
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Decadron · DIN 00016462 · 0.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.Discontinued 2002-07-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Decadron · DIN 00016462 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-07-29 · brand DECADRON TAB 0.5MG · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE .5 MG · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

Decadron: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=286 · Verify on the e-Formulary ↗ (DIN 00016462)

Source record
DIN 00016462: Decadron Raw flags: notABenefit=Y, sec3=Y Item: 680400022; group id 707; item number 1746; lccId None; manufacturer id MSD Source form: Tab; strength: 0.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00016462 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=286
Interchangeable products
Apo-Dexamethasone · DIN 02261081 · $0.1564 PMS-Dexamethasone · DIN 01964976 · $0.1564
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00016462
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.

Decadron · DIN 00354309 · 4mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-08-08 — choose a marketed DIN from the same-category list.Discontinued 2003-08-08 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-08-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-08-08 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Decadron · DIN 00354309 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2003-08-08 · brand DECADRON TAB 4MG · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 4 MG · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

Decadron: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2533 · Verify on the e-Formulary ↗ (DIN 00354309)

Source record
DIN 00354309: Decadron Raw flags: notABenefit=Y, sec3=Y Item: 680400031; group id 707; item number 1747; lccId None; manufacturer id MSD Source form: Tab; strength: 4mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00354309 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2533
Interchangeable products
Apo-Dexamethasone · DIN 02250055 · $0.6112 PMS-Dexamethasone · DIN 01964070 · $0.6112
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00354309
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-08-08 — choose a marketed DIN from the same-category list.

DEXAMETHASONE 21-PHOSPHATE

2 general benefit · 1 not a benefit

Other products in the same Health Canada class (H02AB, S01BA) — coverage varies; not interchangeable

  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pred Forte): general benefit, Not a benefit

7 more in the class list below

Dexamethasone Sodium · DIN 00664227 · 4mg/mL · injection solution

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dexamethasone Sodium · DIN 00664227 Manufacturer: Sandoz Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 2005-09-01 · brand DEXAMETHASONE SODIUM PHOSPHATE INJ USP 4MG/ML · ATC H02AB02 DEXAMETHASONE · form Solution · route Intramuscular, Intrasynovial, Intravenous · ingredients DEXAMETHASONE PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE) 4 MG/ML · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Dexamethasone Sodium: Formulary list price $1.6900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6593 · Verify on the e-Formulary ↗ (DIN 00664227)

Source record
DIN 00664227: Dexamethasone Sodium Raw flags: sec3=Y Item: 680400005; group id 708; item number 1748; lccId None; manufacturer id SDZ Source form: Inj Sol; strength: 4mg/mL Recorded listing: General benefit Source prices (unrounded): $1.6900; ministry $1.6900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00664227 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6593
Interchangeable products
Decadron · DIN 00213624 · not recorded Dexamethasone Sodium · DIN 01977547 · $1.6900
Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00664227
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dexamethasone Sodium · DIN 01977547 · 4mg/mL · injection solution

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dexamethasone Sodium · DIN 01977547 Manufacturer: Sterimax Inc.; listing date 1996-12-19 Health Canada: Marketed since 2015-07-31 · brand DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP · ATC H02AB02 DEXAMETHASONE · form Solution · route Intra-articular, Intramuscular, Intravenous · ingredients DEXAMETHASONE PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE) 4 MG/ML · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Dexamethasone Sodium: Formulary list price $1.6900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13255 · Verify on the e-Formulary ↗ (DIN 01977547)

Source record
DIN 01977547: Dexamethasone Sodium Raw flags: sec3=Y Item: 680400005; group id 708; item number 1748; lccId None; manufacturer id STE Source form: Inj Sol; strength: 4mg/mL Recorded listing: General benefit Source prices (unrounded): $1.6900; ministry $1.6900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01977547 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13255
Interchangeable products
Decadron · DIN 00213624 · not recorded Dexamethasone Sodium · DIN 00664227 · $1.6900
Shortage status: active shortage (reported 2026-04-10, estimated to end 2026-11-30, last updated 2026-08-19) · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01977547
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Decadron · DIN 00213624 · 4mg/mL · injection solution

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-08-01 — choose a marketed DIN from the same-category list.Discontinued 2001-08-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Decadron · DIN 00213624 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2001-08-01 · brand DECADRON PHOSPHATE INJ 4MG/ML · ATC H02AB02 DEXAMETHASONE · form Liquid · route Intravenous, Intramuscular · ingredients DEXAMETHASONE SODIUM PHOSPHATE 4 MG/ML · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

Decadron: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1369 · Verify on the e-Formulary ↗ (DIN 00213624)

Source record
DIN 00213624: Decadron Raw flags: notABenefit=Y, sec3=Y Item: 680400005; group id 708; item number 1748; lccId None; manufacturer id MSD Source form: Inj Sol; strength: 4mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00213624 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1369
Interchangeable products
Dexamethasone Sodium · DIN 00664227 · $1.6900 Dexamethasone Sodium · DIN 01977547 · $1.6900
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00213624
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2001-08-01 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE, PREDNISOLONE ACETATE 52:08 Anti-Inflammatory Agents

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

PREDNISOLONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Oph Susp

KETOROLAC TROMETHAMINE

· 3 products · General benefit · strengths: 0.5%, 0.45% w/v · Oph Sol, Oph Sol-0.4mL Vial Pk (Preservative-Free)

BROMFENAC

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.07% w/v · Oph Sol (With Preservative)

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Actuation · Nas Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L

PREDNISONE

· 7 products · General benefit (5), Listed, not a benefit (2) · strengths: 1mg, 5mg, 50mg · Tab

TRIAMCINOLONE ACETONIDE

· 3 products · General benefit · strengths: 40mg/mL, 50mg/5mL, 200mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

TRIAMCINOLONE HEXACETONIDE

· 1 products · Limited Use, codes 580 · strengths: 20mg/mL · 1mL-Amp Pk

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 4 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MAXIDEX® (dexamethasone ophthalmic ointment, USP and dexamethasone ophthalmic suspension, BP) is indicated for: • Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, iritis, cyclitis, and selected infective conjunctivitis when the inherit hazard of steroid use is acceptable to obtain an advisable diminution in edema and inflammation. • Corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of MAXIDEX in children have not been established. 1.2 Geriatrics Geriatrics (> 60 years of age): No overall differences in safety or effectiveness have been observed between elderly and younger patients. https://pdf.hres.ca/dpd_pm/00072175.PDF PM date: April 01, 2001 Source product: MAXIDEX; DIN 00042560; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Dexamethasone Sodium Phosphate Injection USP may be given by IV or IM injection when oral therapy is not feasible in the following conditions: Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic glucocorticoids may be used in conjunction with a mineralocorticoid where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic glucocorticoids are used). Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Rheumatic Disorders: As adjunctive therapy for short term administration (to support the patient during an acute period of exacerbation) in post-traumatic osteoarthritis, synovitis of osteoarthritis, rheumatoid arthritis,… https://pdf.hres.ca/dpd_pm/00083916.PDF PM date: March 17, 2026 Source product: DEXAMETHASONE SODIUM PHOSPHATE INJ USP 4MG/ML; DIN 00664227; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Dexamethasone Sodium · DIN 00664227 Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00664227

Check this DIN again

Dexamethasone Sodium · DIN 01977547 Shortage status: active shortage (reported 2026-04-10, estimated to end 2026-11-30, last updated 2026-08-19) · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01977547

Check this DIN again

Other review policies

For Decadron: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026